Quarterly ResultAug 6, 2026, 07:08 AM
Amylyx Q2 Net Loss $(43.4)M; Cash $49.3M; Settles Lawsuit
AI Summary
Amylyx Pharmaceuticals reported a net loss of $(43.4) million for the second quarter of 2026, an increase from $(41.4) million in the prior year period. Year-to-date net loss also widened to $(84.7) million. The company's cash and cash equivalents significantly decreased to $49.3 million as of June 30, 2026, though marketable securities saw a substantial increase. Additionally, Amylyx reached an agreement in principle to settle a class action lawsuit for $6.5 million, with a significant portion covered by insurance.
Key Highlights
- Q2 2026 net loss was $(43.4) million, compared to $(41.4) million in Q2 2025.
- Year-to-date net loss was $(84.7) million, up from $(77.3) million in 2025.
- Cash and cash equivalents decreased to $49.3 million from $226.7 million at year-end 2025.
- Marketable securities increased to $201.4 million from $90.3 million at year-end 2025.
- Net cash used in operating activities was $(68.3) million year-to-date.
- Total operating expenses increased to $89.5 million year-to-date.
- Total stockholders' equity decreased to $239.2 million from $305.3 million.
- Agreed to settle a class action lawsuit for $6.5 million, largely insurance-funded.
Price Impact
More from AMLX